Integrated Filing (Financial) for the Quarter and Year ended on 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited filed its audited standalone financial results for Q4 and FY25, showing revenue from operations of Rs. 241.43 lakhs (vs Rs. 2.24 lakhs last year) and a swing to profit after tax of Rs. 16.39 lakhs (vs a loss of Rs. 26.41 lakhs in FY24). Basic EPS for the year stood at Rs. 0.47, compared to a loss per share of Rs. 0.76 earlier. The statutory auditor M/s Maak & Associates issued a Qualified Opinion because balance confirmations for trade receivables and trade payables were not provided, leaving uncertainty over figures in the balance sheet. The company's accumulated losses of Rs. 361.74 lakhs have wiped out its equity, leaving net worth negative at Rs. (15.15) lakhs, raising serious going concern concerns. Cash from operations was negative at Rs. (36.17) lakhs, and total borrowings of around Rs. 511 lakhs sit against negative equity.
While the top-line jump and return to profit look positive on the surface, the negative net worth, qualified audit opinion, and negative operating cash flow signal weak financial health and sustainability risks for shareholders. Investors should view the headline profitability cautiously given the going concern flags and the auditor's inability to verify key receivables and payables.